Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 27, 2026, titled "Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting".
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma announced it will present 14 abstracts at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver (March 27-31, 2026). Key highlights include Phase 3b data on ILUMYA for nail psoriasis showing 52-week efficacy, pooled Phase 3 trial data on LEQSELVI showing scalp hair regrowth in severe alopecia areata patients as early as Week 8, and a 52-week study on WINLEVI for acne showing reduced sebum production. The company also set up an interactive booth (#2915) to engage clinicians. This is a scientific/research showcase with no new product approvals, financial guidance, or order announcements.
Neutral for investors in the short term. The presentation of clinical data at a major global dermatology conference supports Sun Pharma's specialty dermatology portfolio positioning but does not involve new approvals, revenue contracts, or guidance changes that would move the stock price materially.